Literature DB >> 28460617

Impact of IL-12 in Cancer.

Xinjie Lu1.   

Abstract

BACKGROUND: Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably.
METHODS: In this review, we describe the structural features of IL-12 family and their roles involved in cancer.
RESULTS: IL-12 has been demonstrated to regulate both innate (natural killer cells) and adaptive (cytotoxic T lymphocytes) immunities in cancer therapy. This cytokine has been proposed as a potential new agent to be developed in cancer immunotherapy studies due to its impressive antitumor effects in many animal models. In addition, the antitumor activity of IL-12 can be efficiently induced by itself as well as significantly improved by its combination with various treatment modalities including antibodies, antiangiogenic agents, radiotherapy, adoptive therapy, and anti-tumor vaccines.
CONCLUSION: IL-12 has potential roles in anticancer therapy. The advantages of using immunotherapeutic approaches in clinical trials have been reported recently. However, the mechanisms to underlay the immunoregulation and antitumor activities of IL-12 itself, as well as its combination, remain under investigation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  IL-12; NK cells; Th1 pathway; cancer; immunotherapy; receptor

Mesh:

Substances:

Year:  2017        PMID: 28460617     DOI: 10.2174/1568009617666170427102729

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  28 in total

Review 1.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 2.  Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer.

Authors:  Qi Liu; Wei Sun; Hao Zhang
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

Review 3.  Dairy consumption and hepatocellular carcinoma risk.

Authors:  Bodo C Melnik
Journal:  Ann Transl Med       Date:  2021-04

Review 4.  Immune Landscape of Thyroid Cancers: New Insights.

Authors:  Elisa Menicali; Martina Guzzetti; Silvia Morelli; Sonia Moretti; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

5.  CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.

Authors:  Gray Kueberuwa; Milena Kalaitsidou; Eleanor Cheadle; Robert Edward Hawkins; David Edward Gilham
Journal:  Mol Ther Oncolytics       Date:  2017-12-19       Impact factor: 7.200

Review 6.  Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.

Authors:  Álvaro Machado; Tiago Torres
Journal:  Psoriasis (Auckl)       Date:  2018-11-13

Review 7.  NHS-IL12, a Tumor-Targeting Immunocytokine.

Authors:  John W Greiner; Y Maurice Morillon; Jeffrey Schlom
Journal:  Immunotargets Ther       Date:  2021-05-27

8.  GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.

Authors:  Premal H Thaker; William H Bradley; Charles A Leath; Camille Gunderson Jackson; Nicholas Borys; Khursheed Anwer; Lauren Musso; Junko Matsuzaki; Wiam Bshara; Kunle Odunsi; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2021-07-29       Impact factor: 13.801

9.  Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine.

Authors:  Robert O Dillman; Gabriel I Nistor; Aleksandra J Poole
Journal:  Hum Vaccin Immunother       Date:  2019-11-15       Impact factor: 3.452

Review 10.  Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.

Authors:  Curtis W McCloskey; Galaxia M Rodriguez; Kristianne J C Galpin; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.